Skip Navigation

Opinions

  • Print
  • Comment
  • | Share

Backed into a corner, Thailand's action is justified

Source: The Lancet Infectious Diseases

25 June 2007 | EN

World AIDS Day 2006 in Thailand

World AIDS Day 2006 in Thailand

Bangkok Diary

Drug company Abbott Laboratories has backed Thailand into a corner over the pricing of an HIV/AIDS drug, argue Paul Cawthorne and colleagues in this Lancet Infectious Diseases editorial.

Abbott, say the authors, ignored requests to make a newer version of the second-line drug lopinavir-ritonavir available and affordable in Thailand, despite the drug's advantages for tropical countries — no need for refrigeration, no food restrictions and a lower pill requirement.

At US$2,200 per patient annually, the drug has had to be rationed in Thailand — leaving 90 per cent of people who need it without access.

Thailand's decision to issue a compulsory licence for lopinavir-ritonavir was necessary to provide the best possible care for its people, argue Cawthorne and colleagues. Indeed, Thailand's actions fully comply with international intellectual property law.

Developing countries should be able to take action if companies refuse to make essential drugs available at affordable prices.

The fact that Abbott is now withholding new drugs from the Thai market demonstrates a total disregard for public health in developing countries, say the authors.

Link to full article The Lancet Infectious Diseases*

*Free registration is required to view this article.

Add your comment

This is your network: share your views on any of our articles by adding your comments.

You need to be signed in to post a comment or to email a consenting comment author. Please sign in or sign up.

All comments are subject to approval and we reserve the right to edit comments containing inappropriate/unsuitable language. SciDev.Net holds copyright for all material posted on the website. Please see terms of use for further details.

All SciDev.Net material is free to reproduce providing that the source and author are appropriately credited. For further details see Creative Commons.

Back to Opinions
To the top

Information Services